CellSource CoTSE:4880 -2.15%69 Pretax Margin % is 6.10% as of Apr. 2026, which is 75% below its 10-year median of 24.29. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 938 Biotechnology companies, CellSource Co ranks better than 75.91% on this metric.
The historical rank and industry rank for CellSource Co's Pretax Margin % or its related term are showing as below:
TSE:4880'
s Pretax Margin % Range Over the Past 10 Years
Min: 2.96 Med: 24.29 Max: 37.05
Current: 5.32
TSE:4880's Pretax Margin % is ranked better than 75.91% of 938
companies
in the Biotechnology industry
Industry Median: -89.375
vs TSE:4880: 5.32
CellSource Co (TSE:4880) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
CellSource Co Pretax Margin % Related Terms
CellSource Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for CellSource Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, CellSource Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where CellSource Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a Pretax Margin % of 6.10% as of Apr. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CellSource Co and its competitors. This is 75% below median its historical median of 24.29. Over the past decade, CellSource Co's Pretax Margin % has ranged from 2.96 to 37.05. According to the industry distribution chart, CellSource Co ranks #226 out of 938 companies in the Biotechnology industry, placing it in the top 24.1%.
Is CellSource Co's Pretax Margin % too high?
CellSource Co's current Pretax Margin % of 6.10% is 75% below median its 10-year median of 24.29. Over the past 10 years, this metric has ranged from a low of 2.96 to a high of 37.05. Based on the distribution chart, CellSource Co ranks #226 out of 938 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #226 out of 938 companies for Pretax Margin %. This places CellSource Co in the top 24% of its industry — outperforming the majority of peers. Historically, CellSource Co's own Pretax Margin % has ranged from 2.96 to 37.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CellSource Co and its competitors. CellSource Co's current Pretax Margin % is 6.10%, which is 75% below median its own 10-year median of 24.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current Pretax Margin % is 6.10%, which is 75% below median its 10-year median of 24.29. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Pretax Margin % is 6.10% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Pretax Margin %: 6.10% (75% below median its 10-year median of 24.29)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
